Japan – Talk Bio

Japan Approves Anti-CD19 Monoclonal Antibody UPLIZNA for Suppression of Relapse in Immunoglobulin G4-Related Disease (IgG4-RD)

3 weeks ago talkbio0Tagged Anti-CD19 Monoclonal Antibody, Approved, IgG4-RD, IgG4-Related Disease, Immunoglobulin IgG4, inebilizumab, Japan, Ministry of Health, MITIGATE trial, Mitsubishi Tanabe Pharma, Relapse, Uplizna, Visual Suppression, Welfare

UPLIZNA; Inebilizumab; Anti-CD19 monoclonal antibody; IgG4-related disease (IgG4-RD); Immunoglobulin G4; Japan approval; Relapse suppression; MITIGATE trial; Mitsubishi Tanabe Pharma; Ministry of Health, Labour and Welfare

Nxera Pharma to Cut 15% of Workforce in Japan and UK as Part of Restructuring Plan

3 weeks ago talkbio0Tagged GPCR pipeline, Japan, Nxera Pharma, Optimization, Organization administrative structures, profitability, restructuring, Surgical aspects, UK, Workforce reduction

Nxera Pharma; workforce reduction; restructuring; Japan; UK; R&D operations; profitability; GPCR pipeline; organizational optimization

Unlocking Japan’s Potential in Rare Disease Drug Development: Recent Progress and Challenges (2025)

1 month ago talkbio0Tagged Clinical Trials, drug lag, Drugs, Orphan, innovation, Japan, pharmaceutical partnerships, Rare Diseases, regulatory approval

rare disease; Japan; orphan drug; drug lag; innovation; regulatory approval; pharmaceutical partnerships; clinical trials

Ono Pharmaceutical and Jorna Therapeutics Announce AI-Driven Research Pact to Develop Novel RNA Editing Medications

3 months ago talkbio0Tagged Artificial Intelligence, Dosage Forms, Japan, Jorna, RNA Editing, SkyEngine

Ono Pharmaceutical; Jorna Therapeutics; RNA editing; AI drug discovery; SkyEngine; biotech partnership; Japan

Japan Wins Exemption for Generics in US-Japan Trade Deal

3 months ago talkbio0Tagged generic pharmaceuticals, Japan, semiconductor supply chains, tariff exemption, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.

Japan; US Trade Deal; generic pharmaceuticals; tariff exemption; semiconductor supply chains; Trump administration

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

4 months ago talkbio0Tagged Antibodies, Biopharma, Clinical Trials, Dosage Forms, Japan, Kissei, Partnership, Thyroid associated opthalmopathies, Veligrotug, Viridian, VRDN-003

Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal